Biotech News

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

BridgeBio (BBIO)BridgeBioEarnings

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its third quarter 2026 financial results and business update after the market closes on Thursday, October 29, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

Related news

BridgeBio

Genetically Defined Diseases BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs. Attruby Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors...

Recent company news

Stock data

Close
74.27 USD
Market cap
12.51B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States